🛡 Cleerly raises $106M from Insight Partners for AI heart health early detection Heart disease is the leading cause of death in the U.S., yet many individuals who suffer heart attacks are unaware of their underlying conditions. Cleerly, a cardiovascular imaging startup founded by cardiologist James Min in 2017, aims to address this by using AI software to analyze CT scans and detect early-stage coronary artery disease, akin to cancer screenings. The company is conducting a large clinical trial to show that its screening method can identify heart conditions more accurately than traditional approaches like blood pressure and cholesterol tests. Recently, Cleerly raised $106 million in a Series C extension round, adding to a previous $223 million raised within two years, attracting significant investor interest due to its growth potential. While the company awaits full FDA clearance for general heart screening, its algorithms are already approved for diagnosing symptomatic patients, and Medicare has approved coverage for its plaque analysis test. Cleerly's AI-driven analysis is less invasive than traditional methods, and its software has been commercially available for four years, boasting over 100% annual growth. With recognition from health insurers and Medicare for its diagnostic method, Cleerly is well-positioned for continued growth. However, it faces competition from other companies like HeartFlow and Elucid, all aiming to screen a broader population for heart disease. 💬 Source 📌 Powered by V3V Ventures